Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 11, 2011

Primary Completion Date

October 30, 2014

Study Completion Date

March 1, 2018

Conditions
Renal DiseaseRenal Transplant
Interventions
DRUG

Tacrolimus - Prograf® twice daily formulation

twice daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant

DRUG

Tacrolimus - Advagraf® once daily formulation

once daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant

Trial Locations (1)

V5Z 1M9

Solid Organ Transplant Clinic, Vancouver General Hospital, Vancouver

All Listed Sponsors
collaborator

Simon Fraser University

OTHER

collaborator

Astellas Pharma Canada, Inc.

INDUSTRY

lead

University of British Columbia

OTHER

NCT01334333 - Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients | Biotech Hunter | Biotech Hunter